NPHC stock performance?

Nutra Pharma Corp. (NPHC) financial news, and detailed stock charts

This company symbol is outdated. Results displayed are archieved for your information

Nutra Pharma Corp. (NPHC/NPHC.OB) Stock Summary:

Nutra Pharma Corp., a biopharmaceutical company, engages in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. The company, through its subsidiary, ReceptoPharm, Inc., develops RPI-78M for the treatment of neurological diseases, multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, and myasthenia gravis; and RPI-MN for the treatment of the viral diseases, HIV/AIDS, and hepatitis-C. In addition, the company, through its other subsidiary, Designer Diagnostics, Inc., engages in the sale of diagnostic test kits that are used for the identificat...
3 Employees
Last Reported Date: 03/31/14
Founded in 2000
Last $0.0077 USD
Change Today -0.0004 / -4.94%
Volume 1.5M
As of 5:10 PM 07/3/14 All times are local (Market data is delayed by at least 15 minutes).

nutra pharma corp (NPHC) Snapshot

Open
$0.0077
Previous Close
$0.0081
Day High
$0.0081
Day Low
$0.0076
52 Week High
09/5/13 - $0.03
52 Week Low
05/9/14 - $0.0030
Market Cap
8.7M
Average Volume 10 Days
8.0M
EPS TTM
$-0.0042
Shares Outstanding
1.1B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Request Investor Kit
NPHC:US Advanced Stock Chart

Related News

No related news articles were found.

nutra pharma corp (NPHC) Related News

No Related News Found

nutra pharma corp (NPHC) Key Developments

Nutra Pharma Announces Completion of Commercials by MyNyloxin.com

Nutra Pharma Corp. announced that MyNyloxin.com has the exclusive rights to market and distribute Nutra Pharma's over-the-counter (OTC) pain reliever, Nyloxin(R), in the Network Marketing channel, has completed their work on a series of commercials to start airing in the month of June 2014. The advertisements focus on the benefits of Nyloxin(R) and include 30 second, 60 second and 120 second spots.

Nutra Pharma Corporation announced delayed 10-Q filing

On 05/16/2014, Nutra Pharma Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

Nutra Pharma Finalizes Exclusive Network Marketing Distribution Agreement for Nyloxin

Nutra Pharma Corp. is announcing that MyNyloxin will have the exclusive rights to market and distribute Nutra Pharma's over-the-counter (OTC) pain reliever, Nyloxin(R), in the Network Marketing channel. Nutra Pharma will continue to market the products through their retail and Direct Response distributors. In September 2012, Nutra Pharma announced the beginning of distribution efforts by the TCN group of direct distributors. Since that time, TCN has worked diligently to introduce Nyloxin(R) to approximately 40,000 distributors in the United States and almost 400,000 distributors globally. TCN has now created a stand-alone opportunity for distributors under the name MyNyloxin. The launch will take place throughout the month of December and will include webinars, internet, radio and television advertising.

Nutra Pharma Corp. financial resources

otc, otcbb, pinksheet, NPHC, ob Nutra Pharma Corp.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NPHC:US $0.01 USD -0.0004

NPHC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NPHC.
 

Industry Analysis

NPHC

Industry Average

Valuation NPHC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 51.1x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 44.7x
 | 

Post a JobJobs

  • Manufacturing Operations Lead
    New York City, NY | D. E. Shaw Research
    Posted: Jun 13
  • Head of Engineering Program Management
    New York City, NY | D. E. Shaw Research
    Posted: Jun 09
  • Engineering Program Managers
    New York City, NY | D. E. Shaw Research
    Posted: Jun 09
  • Houston, TX | Aerotek Engineering & Environmental
    Posted: Jul 02
Simply Hired

Sponsored Financial Commentaries

Sponsored Links

Archieved Financial News About Nutra Pharma Corp.

NUTRA PHARMA CORP Files SEC form 10-Q, Quarterly Report

Quote: The article, "Cobra Venom: A Review of the Old Alternative to Opiate Analgesics," was published in the January, 2011 issue of the journal, Alternative Therapies in Health and Medicine. On January 20, 2011 we announced that we provided an educational grant for the Pharmacist Continuing Education course "Over-the-Counter Use of Neuroactive Peptides for the Treatment of Chronic Pain." The course is available through Power Pak and the publication, US Pharmacist. We posted 23 arti...
Read article

Nutra Pharma Receives Regulatory Approval to Market Nyloxin in India

Keywords: Nutra Pharma Receives Regulatory Approval to Market Nyloxin in India, nphc.ob
Quote: Following the approval, Nutra Pharma hasaccepted orders for the products through their distributor, NutritionalAlliance, for export to India-based importers.“The India approval is our first regulatory authorization overseas andrepresents one of the more significant international marketopportunities for Nyloxin,” commented Rik J Deitsch, Chairman and CEO ofNutra Pharma Corporation. “With the population of India exceeding abillion people and with limited patient access to opioid-...
Read article

Nutra Pharma Announces Jordan Distributor for Their Nyloxin Pain Relievers

Keywords: Nutra Pharma Announces Jordan Distributor for Their Nyloxin Pain Relievers, nphc.ob
Quote:
Read article

Nutra Pharma Announces Exclusive Distributor for Their Nyloxin Pain Relievers in Lebanon

Keywords: Nutra Pharma Announces Exclusive Distributor for Their Nyloxin Pain Relievers in Lebanon, nphc.ob
Quote: NPHCNewsAlampharm to serve as the exclusive distributor in Lebanon for its Nyloxinâ„¢-branded pain relievers.Nutra Pharma Corporation. "As the leading pharmaceutical distributor in Lebanon, Alampharm is the perfect partner to introduce and distribute our products into the Middle East," he added.Alampharm is a leading pharmaceutical company operating in Lebanon and highly recognized in the Middle East. Alampharm maintains the highest quality customer service by ensuring the safety of the prod...
Read article

NUTRA PHARMA CORP Files SEC form 10-Q, Quarterly Report

Quote: The article, "Cobra Venom: A Review of the Old Alternative to Opiate Analgesics," was published in the January, 2011 issue of the journal, Alternative Therapies in Health and Medicine. On January 20, 2011 we announced that we provided an educational grant for the Pharmacist Continuing Education course "Over-the-Counter Use of Neuroactive Peptides for the Treatment of Chronic Pain." The course is available through Power Pak and the publication, US Pharmacist. We posted 23 arti...
Read article

Nutra Pharma Announces Exclusive Distributor for Their Nyloxin Pain Relievers in Venezuela

Keywords: Nutra Pharma Announces Exclusive Distributor for Their Nyloxin Pain Relievers in Venezuela, nphc.ob
Quote: NPHCNews), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain announced today that it has selected Pentanet CA to serve as the exclusive distributor in Venezuela for its Nyloxin-branded pain relievers.Nutra Pharma Corporation. "As one of the leading pharmaceutical distributors in Venezuela, Pentanet brings the expertise and ability to support the growth of new healthcare products such as Nylo...
Read article

Nutra Pharma Announces Nyloxin(TM) Distribution Through Innovatix

Keywords: Nutra Pharma Announces Nyloxin(TM) Distribution Through Innovatix, nphc.ob
Quote: NPHCNewsInnovatixNyloxinâ„¢ throughout the United States and particularly to the Long-Term Care and Senior Markets.Nutra Pharma Corporation. "The aging population includes the primary users of narcotic pain drugs. These drugs can cause a range of side effects that may actually speed the decline of these patients. Nyloxinâ„¢ will allow seniors to greatly reduce their pain and inflammation without the subsequent loss of cognitive function. Innovatix is the right organization to market dire...
Read article

Nutra Pharma Receives Patent for the Use of Cobratoxin as an Analgesic

Keywords: Nutra Pharma Receives Patent for the Use of Cobratoxin as an Analgesic, nphc.pk
Quote: NPHCNewspatent describing the use of cobratoxin as a treatment for chronic pain."This patent represents a key addition to our intellectual property portfolio," commented Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "As we continue our efforts developing treatments for chronic pain using proteins from cobra venom, this patent will provide important ongoing support and protection of our research and development projects," he explained.The patent (US 7,902,152), titled "Use of cobra...
Read article

Nutra Pharma Announces Publication of a Review Article on Cobra Venom and Its Use as an Analgesic

Keywords: Nutra Pharma Announces Publication of a Review Article on Cobra Venom and Its Use as an Analgesic, nphc.ob
Quote: NPHCNewsAlternative Therapies in Health and MedicineReceptoPharm.Nutra Pharma Corporation. "This further emphasizes the need and potential efficacy of venom-based therapeutics like Cobroxin and Nyloxin," he concluded.CobroxinNyloxin™ and Nyloxin™ Extra Strength, stronger versions of Cobroxin®. These products are currently available in the United States as an oral spray for treating back pain, neck aches, headaches, joint pain, migraines, and neuralgia, and as a topical gel for tre...
Read article

Nutra Pharma Awarded Grant Under the Qualifying Therapeutic Discovery Project Program

Keywords: Nutra Pharma Awarded Grant Under the Qualifying Therapeutic Discovery Project Program, nphc.ob
Quote: Press ReleaseSource: Nutra Pharma CorporationOn Friday November 5, 2010, 9:02 am CORAL SPRINGS, FL--(Marketwire - 11/05/10) - Nutra Pharma Corporation (OTC.BB: - "It is an honor to receive this grant and to be recognized by the United States Federal Government for our work developing novel analgesics," commented Rik J Deitsch, Chairman and CEO of . "We intend to use the proceeds from this grant to support our ongoing clinical development program for our pain relievers, which includeandNutra Phar...
Read article

Nutra Pharma Selects Nutritional Alliance as Its Global Sales Agent

Keywords: Nutra Pharma Selects Nutritional Alliance as Its Global Sales Agent, nphc.ob
Quote: Press ReleaseSource: Nutra Pharma CorporationOn Tuesday October 26, 2010, 9:02 am EDTCORAL SPRINGS, FL--(Marketwire - 10/26/10) - Nutra Pharma Corporation (OTC.BB: - ), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), Multiple Sclerosis (MS) and Pain, announced today that it has selectedto serve as its global sales agent for its "We are pleased to introduce Nutritional Alliance as our global sales agent. This relationship ...
Read article

Nutra Pharma Introduces Nyloxin for Pets -- a Treatment for Moderate to Severe Chronic Pain in Companion Animals

Keywords: Nutra Pharma Introduces Nyloxin for Pets -- a Treatment for Moderate to Severe Chronic Pain in Companion Animals, nphc.ob
Quote: Press ReleaseSource: Nutra Pharma CorporationOn Monday September 27, 2010, 9:03 am EDTCORAL SPRINGS, FL--(Marketwire - 09/27/10) - Nutra Pharma Corporation (OTC.BB: - ), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), Multiple Sclerosis (MS) and Pain, introduced today "Companion animals play an important role in our homes and communities and are, oftentimes, considered extended members of the family," commented , Chairman...
Read article

Nutra Pharma Begins Drug Registration Process in India for Nyloxin -- A Treatment for Moderate to Severe Chronic Pain

Keywords: Nutra Pharma Begins Drug Registration Process in India for Nyloxin -- A Treatment for Moderate to Severe Chronic Pain, nphc.ob
Quote: An additional 2007 report from the Journal of Pain and Symptom Management, documented that only 0.4% of India's population in need of opioids for pain relief had access to them.Rik J DeitschNutra Pharma Corporation. "With the population of India exceeding a billion people and with limited patient access to opioid-based pain relievers throughout the country, India presents a potentially significant customer base for Nyloxin," he added.Nyloxin, which was first introduced in November 2009 as a trea...
Read article

NUTRA PHARMA CORP Files SEC form 8-K, Change in Directors or Principal Officers

Quote: NUTRA PHARMA CORPRequest a Trial to NEW EDGAR Online Pro Form 8-K for NUTRA PHARMA CORP 18-Aug-2010Change in Directors or Principal OfficersPrivacy PolicyAbout Our AdsTerms of ServiceCopyright/IP PolicySend Feedback - Yahoo! News NetworkSEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any infor...
Read article

Nutra Pharma Announces Amarey Nova Medical as Its Exclusive Nyloxin Distributor in Colombia

Keywords: Nutra Pharma Announces Amarey Nova Medical as Its Exclusive Nyloxin Distributor in Colombia, nphc.ob
Quote: Press ReleaseSource: Nutra Pharma CorporationOn Monday August 9, 2010, 9:01 am EDTCORAL SPRINGS, FL--(Marketwire - 08/09/10) - Nutra Pharma Corporation (OTC.BB: - "We are excited to be working with Amarey Nova Medical to introducethroughout the Colombian healthcare market," explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the m...
Read article

Nutra Pharma Announces Second Quarter 2010 Sales and Distribution Update

Keywords: Nutra Pharma Announces Second Quarter 2010 Sales and Distribution Update, nphc.ob
Quote: Previously, the Company had realized sales of $583,955 in the fourth quarter of 2009 and $864,424 in the first quarter of 2010."Second quarter sales were disappointing, especially after we saw the early growth at the beginning of the year," commented Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "The primary reason for the decrease in sales is the lack of advertising and marketing exposure by our licensee, XenaCare Holdings," he continued. "Additionally, many of the large retailer...
Read article

NUTRA PHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibit

Quote: NUTRA PHARMA CORPRequest a Trial to NEW EDGAR Online Pro Form 8-K for NUTRA PHARMA CORP 6-Aug-2010Results of Operations and Financial Condition, Financial Statements and Exhibit Privacy PolicyAbout Our AdsTerms of ServiceCopyright/IP PolicySend Feedback - Yahoo! News NetworkSEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of indepen...
Read article

Nutra Pharma Receives Patent for Novel Antiviral Treatment Using Modified Cobra Venom

Keywords: Nutra Pharma Receives Patent for Novel Antiviral Treatment Using Modified Cobra Venom, nphc.ob
Quote: Gamma interferon is considered a potent antiviral agent and regulator of the immune response.Nutra Pharma Corporation. "As we continue our efforts developing antiviral therapies using proteins from cobra venom, this patent will provide important ongoing support and protection of our research and development projects," he explained.ReceptoPharm, introduced its novel antiviral therapy, PEPTERON, at the International AIDS Conference in Vienna, Austria. PEPTERON is based on the Company's leading dru...
Read article

Nutra Pharma Drug Discovery Subsidiary to Introduce Novel Antiviral Therapy at the International AIDS Conference in Vienna, Austria

Keywords: Nutra Pharma Drug Discovery Subsidiary to Introduce Novel Antiviral Therapy at the International AIDS Conference in Vienna, Austria, nphc.ob
Quote: GSK is currently one of the largest providers of HIV antiretroviral drugs.Rik J DeitschNutra Pharma Corporation. "As we move forward with our HIV clinical development program, we intend to actively seek out international collaborations and partnerships that will help leverage our ability to bring PEPTERON through the regulatory approval process," he said.The International AIDS Conference, which began on July 18 and runs through July 23, 2010, is considered one of the premier conferences for thos...
Read article

Nutra Pharma Begins Drug Registration Process in Central America for Its Nyloxin Pain Reliever

Keywords: Nutra Pharma Begins Drug Registration Process in Central America for Its Nyloxin Pain Reliever, nphc.ob
Quote: NPHCNews), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), announced today that it has begun the drug registration process in PanamaNyloxin pain reliever.Rik J DeitschNutra Pharma. "We plan to move forward with this drug registration process in conjunction with finalizing our relationship with a prospective local distribution partner that has the resources and capabilities to successfully market and distribute Nyloxin throug...
Read article

You can still leave a comment about Nutra Pharma Corp. NPHC/NPHC.OB

Besides Nutra Pharma Corp.'s Stock there is more great Microcap and Stock Market information available at Realpennies.com